X-Chem, Inc. has licensed a second drug discovery program to Bayer Pharma AG under a multi-target collaboration established in July 2012. The latest program includes a series of small molecule compounds against a cardiovascular drug target. X-Chem will receive an upfront license fee in addition to preclinical, clinical, sales milestones, as well as royalties. The financial terms were not disclosed.   “This license further validates the innovative nature of X-Chem’s team and approach,” said Prof....